CD70 is a novel therapeutic target for EGFR mutant NSCLC with acquired, EMT-associated EGFR TKI resistance

被引：0

作者：

Nilsson, Monique B. ^{[1
]}

Yang, Yan ^{[1
]}

Patel, Sonia ^{[1
]}

Heeke, Simon ^{[1
]}

Le, Xiuning ^{[1
]}

Aruguman, Thiru ^{[1
]}

Robichaux, Jacqulyne ^{[1
]}

Yu, Xiaoxing ^{[1
]}

Poteete, Alissa ^{[1
]}

Ren, Xiaoyang ^{[1
]}

Diao, Lixia ^{[1
]}

Shen, Li ^{[1
]}

Wang, Qi ^{[1
]}

Zhang, Fahao ^{[1
]}

Clemente, Leticia Campos ^{[1
]}

Soto, Luisa Solis ^{[1
]}

Shi, Chunhua ^{[1
]}

Tran, Hai ^{[1
]}

Bock, Jason ^{[1
]}

Wang, Jing ^{[1
]}

Wistuba, Ignacio I. ^{[1
]}

Minna, John D. ^{[2
]}

Heymach, John V. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Univ Texas SouthWestern Med Ctr, Dallas, TX USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1827

引用

页数：1

共 50 条

[21] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Wenxian Wang
Hong Wang
Peihua Lu
Zongyang Yu
Chunwei Xu
Wu Zhuang
Zhengbo Song
Journal of Translational Medicine, 17
[22] Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Weng, Chien-Hui
Chen, Li-Yu
Lin, Yu-Chin
Shih, Jin-Yuan
Lin, Yun-Chieh
Tseng, Ruo-Yu
Chiu, An-Chieh
Yeh, Yu-Hsuan
Liu, Chi
Lin, Yi-Ting
Fang, Jim-Min
Chen, Ching-Chow
ONCOGENE, 2019, 38 (04) : 455 - 468
[23] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Wang, Wenxian
Wang, Hong
Lu, Peihua
Yu, Zongyang
Xu, Chunwei
Zhuang, Wu
Song, Zhengbo
JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
[24] Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Chien-Hui Weng
Li-Yu Chen
Yu-Chin Lin
Jin-Yuan Shih
Yun-Chieh Lin
Ruo-Yu Tseng
An-Chieh Chiu
Yu-Hsuan Yeh
Chi Liu
Yi-Ting Lin
Jim-Min Fang
Ching-Chow Chen
Oncogene, 2019, 38 : 455 - 468
[25] Mechanisms of intrinsic and acquired resistance to third generation inhibitors in EGFR mutant NSCLC
Niederst, Matt J.
CANCER RESEARCH, 2015, 75
[26] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
D. Zheng
X. Ye
M. Z. Zhang
Y. Sun
J. Y. Wang
J. Ni
H. P. Zhang
L. Zhang
J. Luo
J. Zhang
L. Tang
B. Su
G. Chen
G. Zhu
Y. Gu
J. F. Xu
Scientific Reports, 6
[27] NGS reveals potential druggable targets and molecular heterogeneity in EGFR mutant NSCLC with acquired resistance to EGFR TKIs
Lee, Choong-Kun
Kim, Sora
Lee, Jae Seok
Kim, Hye Ryun
Kim, Joo-Hang
Kim, Sang Woo
Cho, Byoung Chul
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S586 - S586
[28] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
Zheng, D.
Ye, X.
Zhang, M. Z.
Sun, Y.
Wang, J. Y.
Ni, J.
Zhang, H. P.
Zhang, L.
Luo, J.
Zhang, J.
Tang, L.
Su, B.
Chen, G.
Zhu, G.
Gu, Y.
Xu, J. F.
SCIENTIFIC REPORTS, 2016, 6
[29] A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance
Taube, Erika
Jokinen, Elina
Koivunen, Peppi
Koivunen, Jussi P.
INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (04) : 970 - 979
[30] Chronic inhibition of mutant EGFR in NSCLC leads to EGFR TKI resistance by TGF-β1 mediated epithelial to mesenchymal transition
Shimamura, Takeshi
Carretero, Julian
Xu, Chunxiao
Capelletti, Marzia
Rikova, Klarisa
Gu, Ting-Lei
Kobayashi, Susumu
Rogers, Andrew
Janne, Pasi A.
Wong, Kwok-Kin
Shapiro, Geoffrey I.
CANCER RESEARCH, 2011, 71

← 1 2 3 4 5 →